— Signed an exclusive business agreement with the Tamil Nadu state government to promote the establishment of a new shipyard — Tamil Nadu state assessed as the most optimal site with climate and rainfall similar to Ulsan, and is expected to have additional large-scale investments in port facilities — Will also be partnering with an […]
(HKSE:6855),(NasdaqGM:AAPG), Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients 80% ORR achieved in newly diagnosed high-risk MDS/CMML Strong safety profile with no dose-limiting toxicities across all patient cohorts in 103-patient study ROCKVILLE, Md. and SUZHOU, China, Dec. 07, 2025 (GLOBE NEWSWIRE)
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Exposed Patients with Myeloid Malignances GlobeNewswire December 08, 2025 Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients 80% ORR achieved in newly diagnosed high-risk
Tyler, TX, Dec. 07, 2025 (GLOBE NEWSWIRE) — Roberts & Roberts Law Firm is offering free rides home this holiday season to help keep East Texas roads safer and reduce impaired driving. The firm's annual campaign, “The Ride is on Us,” provides no-cost rides across a 14-county service area during one of the busiest travel
Hydron Energy, a leading innovator in clean fuel and gas separation technologies, today announced the successful demonstration of carbon-negative Xenon and Krypton production from air. The initiative focused on application of Hydron's next generation metal-organic framework (MOF) in the company's INTRUPTor™ gas separation platform for direct air carbon capture in conjunction with Xenon and Krypton
Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced the initial data of the first-in-human trial of IBI3003, a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen
Roberts & Roberts Law Firm Offers Free Rides Home to Prevent Drunk Driving Roberts & Roberts Law Firm is offering free rides home this holiday season to help keep East Texas roads safer and reduce impaired driving. GlobeNewswire December 08, 2025 Tyler, TX, Dec. 07, 2025 (GLOBE NEWSWIRE) — Roberts & Roberts Law Firm is
The Global Health Innovative Technology (GHIT) Fundannounced today an investment of approximately JPY 70 million (USD 460,0001) for the development of a prototype detection test for mpox (formerly known as monkeypox2). Mpox is a viral infectious disease that has been spreading in the Democratic Republic of the Congo (DRC) and across sub-Saharan Africa. According to
SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinibamong Asian patients. Median overall survival not yet reached and is projected to exceedfour years, which would surpass osimertinib monotherapy by more than one year. Johnson & Johnsontoday announced final overall survival (OS) results from
TenPay Global, Tencent's cross-border payment platform, and Mastercard Move, Mastercard's money movement business, have announced a collaboration to facilitate fast, secure and transparent digital remittances directly to Weixin Pay, a leading mobile payment service within the Weixin ecosystem in China. Through Mastercard Move, Mastercard's portfolio of money movement capabilities, eligible senders around the world will